🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shandong Provincial Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Shandong Provincial Hospital as lead sponsor. Synced 26 Sep 2026
16Current trials
10Recruiting now
5Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shandong Provincial Hospital is the lead sponsor of 16 current clinical trials in our China register. 10 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Henagliflozin, Iparomlimab and Tuvonralimab and Mazdutide. The most-studied condition is Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma.

ClinicalTrials.gov trials by status

  • Recruiting1063%
  • Not yet open425%
  • Active, closed213%

Trials by phase

  • Observational638%
  • Phase 2425%
  • Not applicable319%
  • Phase 4213%
  • Phase 316%
01

Clinical trials sponsored by Shandong Provincial Hospital

16 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
An Empirical Study on the Mechanisms of Biopsychosocial Functional Improvement in Patients With Major Depressive Disorder Through Nature-Based Tourism Activities
NCT07180342 · ClinicalTrials.gov ↗ · Major Depressive Disorder
Not applicable Recruiting 2025-10 China
Endocrine Glucose & Lipids Metabolism and Brain Aging: a Longitudinal Study
NCT06066775 · ClinicalTrials.gov ↗ · Brain Aging Related Conditions
Observational Recruiting 2023-07 China
Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06766578 · ClinicalTrials.gov ↗ · Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 Recruiting 2024-12 China
A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06829797 · ClinicalTrials.gov ↗ · Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 Recruiting 2025-03 China
SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
NCT07284992 · ClinicalTrials.gov ↗ · Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy
Phase 2 Recruiting 2025-09 China
Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy
NCT07527715 · ClinicalTrials.gov ↗ · Cardiomyopathy, Dilated, Prognosis, Magnetic Resonance Imaging, Cardiac
Observational Recruiting 2021-12 China
Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
NCT07549100 · ClinicalTrials.gov ↗ · Locally Advanced Esophageal Squamous Cell Carcinoma
Observational Recruiting 2023-05 China
Iodine Nutrition Status and Clinical Characteristics of Thyroid Cancer
NCT06623500 · ClinicalTrials.gov ↗ · Thyroid Cancer
Observational Recruiting 2012-01 China
The Biological Rhythm of Human Metabolite
NCT03669809 · ClinicalTrials.gov ↗ · Rhythm Nodal, Metabolism and Nutrition Disorder, Metabolism Disorder, Lipid
Observational Recruiting 2011-05 China
Neoadjuvant QL1706 Therapy for ESCC
NCT06908382 · ClinicalTrials.gov ↗ · Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Phase 2 Recruiting 2025-04 China
Henagliflozin's Impact on Prediabetes Remission
NCT06448130 · ClinicalTrials.gov ↗ · PreDiabetes, Prediabetic State, Type 2 Diabetes
Phase 4 Not yet open 2024-06 China
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)
NCT07654062 · ClinicalTrials.gov ↗ · Prediabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance (Prediabetes)
Drug: Mazdutide
Phase 4 Not yet open 2026-07 China
Intra-Arterial Tirofiban After Complete Recanalization for Acute Intracranial Large-Vessel Occlusion
NCT07537933 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke, Large-vessel Occlusion, Endovascular Treatment
Drug: Tirofiban
Phase 3 Not yet open 2026-04 China
Thyroxine Supplementation in Small for Gestational Age (SGA) Infants With Birth Weight <1500g and TSH 6-20 mIU/ml
NCT07625722 · ClinicalTrials.gov ↗ · Thyroid Function, Preterm, SGA and Growth
Not applicable Not yet open 2026-06 China
The Effect of the Application of Head Mounted Magnifying Glasses on Postoperative PTH Changes in Thyroid Surgery: Stage II
NCT06838728 · ClinicalTrials.gov ↗ · Thyroid Surgery
Not applicable Active, closed 2020-01 China
The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study
NCT06096896 · ClinicalTrials.gov ↗ · Early Hepatocellular Carcinoma
Observational Active, closed 2023-08 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shandong Provincial Hospital trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shandong Provincial Hospital trials

32 conditions
Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma2Major Depressive Disorder1PreDiabetes1Prediabetic State1Type 2 Diabetes1Glucose Metabolism Disorders1Brain Aging Related Conditions1Prediabetes1Impaired Fasting Glucose1Impaired Glucose Tolerance (Prediabetes)1Thyroid Surgery1Acute Ischemic Stroke1Large-vessel Occlusion1Endovascular Treatment1Thyroid Function1Preterm1SGA and Growth1Neurodevelopment Outcome1Rectal Cancer1Advanced Stage Colorectal Cancer1Radiotherapy1Cardiomyopathy, Dilated1Prognosis1Magnetic Resonance Imaging, Cardiac1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1610

A trial with sites in more than one country appears in each of those registers.

05

Questions about Shandong Provincial Hospital trials

How many clinical trials does Shandong Provincial Hospital sponsor?

Shandong Provincial Hospital is the lead sponsor of 16 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shandong Provincial Hospital trials recruiting?

Yes. 10 of its 16 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shandong Provincial Hospital testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Henagliflozin (1), Iparomlimab and Tuvonralimab (1), Mazdutide (1), Tirofiban (1) and Tislelizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.